Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
Rinvoq from AbbVie to be available in the US in late August 2019, after receiving FDA approval for the treatment of adults with active rheumatoid arthritis.
Samsung Bioepis’ Renflexis has become the second biosimilar of rheumatoid arthritis biologic Remicade (infliximab) to be recommended for approval in the US.
The US FDA has issued a complete response letter for Sanofi and Regeneron’s rheumatoid arthritis candidate sarilumab due to manufacturing deficiencies at a fill/finish plant in France.
Amid ongoing patent litigation, the FDA has approved Amgen’s Amjevita: the first US biosimilar version of AbbVie’s top selling rheumatoid arthritis biologic Humira.
New auto-injector technology that is user-friendly and capable of delivering high viscosity drugs may be the next big thing for pharma and biotech companies pushing further into niche biologics and biosimilars.
Bristol Myers-Squibb says its $250m (€191m) expansion of its US biologics facility will centralize its processes and become a springboard to launch new products.
Reformulation and delivery tech firm SkyPharma is set for an earnings boost following US approval for rheumatoid arthritis (RA) drug developed by Horizon Pharma.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at INC Research, Velesco, Acurian, Asterand and Cmed.
Rheumatoid arthritis (RA) sufferers may soon have a new treatment delivery option thanks to US delivery specialist Antares Pharma’s partnership with Canadian injectables specialist Uman Pharma.
Following a “significant increase in demand” GVK Biosciences has partnered with Quantitative Solutions (QS) to develop and market clinical trial outcome databases, which they believe can improve drug development.
Galapagos' services arm has scored another lucrative contract from
big pharma - its first in the field of oncology - as it continues
to broaden its experience.
GlaxoSmithKline (GSK) is the latest drug firm to involve Galapagos
in a new development partnership, in a deal worth up to €218m for
the Belgian biotech.
The merger between Mitsubishi Chemical Holding's pharmaceutical
unit and Tanabe Seiyaku has been completed and the new entity is
looking to expand its presence outside Japan and create a more
efficient R&D and manufacturing...
US biotech Medarex has announced it has extended its licensing deal
with Centocor, giving the firm continued access to its antibody
production technology.
Millipore has released a new kit that allows researchers to quickly
generate arthritis mouse models for screening and evaluating
anti-inflammatory therapeutics.
Amgen is rushing to discover how interleukin-17 causes
inflammation and bone destruction in rheumatoid arthritis, as it
could provide a valuable new therapeutic target.
The UK's drug reimbursement watchdog has given the green light for
the first time to a treatment specifically for multiple sclerosis
(MS) and also gave the thumbs up to two arthritis drugs, all of
which are biologics.
Roche has committed hundreds of millions of dollars to an
early-phase rheumatoid arthritis drug, a move that is indicative of
big pharma's increasing tendency to license earlier phase
compounds.
Asterand is to make available novel research materials to be used
in the investigation of rheumatoid arthritis, osteoarthritis,
cancer and other diseases making available a range of cell material
that is currently difficult to obtain.
Biogen has revealed details of a potential new pathway in
rheumatoid arthritis (RA) that could provide unique insights into
the disease process and eventually a new approach to developing RA
therapies.
In an incident Roxane Laboratories warns could have
life-threatening consequences, a manufacturing lot of azathioprine
tablets has been recalled in the US and Puerto Rico following the
discovery of methotrexate tablets in one of its...
EntreMed has produced hard data demonstrating antiangiogenic
activity of its lead compound against the devastating effects of
rheumatoid arthritis (RA). The results pave the way to developing
therapeutics for the cancer and inflammatory...
Lonza has been authorised by the US Food and Drug Administration
(FDA) to produce Bristol-Myers Squibb's arthritis drug Orencia
(abatacept), in what is shaping up to be a major manufacturing deal
for the Swiss company.
Rigel has completed the Phase I stage of its drug interaction study
in patients with rheumatoid arthritis. The oral syk kinase
inhibitor could be an improvement over current treatment options,
which have side effects that include...
Scientists exploring inflammation in rheumatoid arthritis have made
an unexpected discovery that may lead to new drug treatments to
ease the pain and discomfort endured by 66 million (nearly 1 in 3
adults) US citizens in 2005.
Lonza has scored a manufacturing contract to help Bristol
Myers-Squibb (BMS) meet anticipated demand of its newly approved
drug that will offer a new treatment option for rheumatoid
arthritis, a disease that afflicts more than two...
Domantis has announced an alliance with pharma giants Bristol-Myers
Squibb to develop human Domain Antibody (dAb) products, a novel
approach to address therapeutic targets involved in T-cell
co-stimulation.
Pfizer and Incyte have entered a collaborative research and license
agreement for the development and commercialisation of CCR2
antagonists - an emerging class of drug that aims to serve an unmet
need in the treatment of rheumatoid...
Scientists have synthesised a lab-made version of a human protein,
which alleviates symptoms of both acute and chronic arthritis. The
study opens new research avenues to better understand and develop
drug treatments for rheumatoid...
In the wake of its £1.53 billion acquisition of UK biotechnology
company Celltech, Belgium's UCB has disclosed a near 60 per cent
hike in R&D funding for 2005.
Bristol-Myers Squibb has reported encouraging data from two
late-stage trials of a new drug for rheumatoid arthritis,
abatacept, the first in a new class of T cell costimulation
modulators.
An antibody drug candidate to treat autoimmune diseases has been
exclusively in-licensed by KaloBios Pharmaceuticals who hope to
develop this compound into a practicable treatment for rheumatoid
arthritis (RA), which currently...
A rheumatoid arthritis drug developed by Franco-German company
Aventis has been linked to the deaths of five patients in Japan,
prompting the company to warn against prescribing the drug to
people with respiratory problems.
German biotechnology company TeGenero has signed up Boehringer
Ingelheim to make clinical trials of its antibody drug in a move
that reflects an emerging trend in the contract manufacturing
sector.
Serono has initiated Phase I clinical testing of TACI-Ig, a soluble
receptor-based drug that may have a role to play in the management
of autoimmune diseases.
Lonza Biotec is to manufacture PEGylated antibody fragment-based
drugs for Celltech under the terms of a new agreement between the
two companies. The two companies have also reached an agreement on
a prior deal relating to Celltech's...
